RxDoctor Payments Data

Christopher Kelly, PA

Physician Assistant · Gilbert, WVNPI 1407137110

Payments from drug & device makers

$765in general payments, 2019–2025

Across 42 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$206
  • Novo Nordisk$114
  • AstraZeneca$76
  • Abbott$67
  • Novartis$58
  • AbbVie$37
  • plus $207 from 10 others

What the payments were for

  • Food & beverage$74597%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$765 in reported general payments places this provider in the 70th percentile of 833 physician assistant providers in West Virginia.

See all physician assistant providers in West Virginia

Medicare billing

Part B allowed, 2024
$1,131
Medicare patients
29
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$216,161
MounjaroTirzepatide149$215,628
FarxigaDapagliflozin Propanediol141$173,538
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$118,987
Repatha SureclickEvolocumab93$78,708
EntrestoSacubitril/Valsartan61$73,773
EliquisApixaban61$67,498
Tresiba Flextouch U-200Insulin Degludec33$60,759
XareltoRivaroxaban36$56,197
TradjentaLinagliptin48$51,175
LinzessLinaclotide37$45,300
VascepaIcosapent Ethyl39$38,514
SynjardyEmpagliflozin/Metformin Hcl39$38,349
Xultophy 100-3.6Insulin Degludec/Liraglutide11$37,889
Humulin R U-500 KwikpenInsulin Regular, Human21$29,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$114$254,050145 claims
Lilly USA, LLCMounjaro, Trulicity$17$241,444166 claims
AstraZenecaFarxiga, Brilinta, Symbicort$76$202,461180 claims
Boehringer IngelheimTradjenta, Synjardy, Synjardy Xr, Jardiance, Jentadueto$206$187,540153 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$14$142,281118 claims
NovartisEntresto$58$73,77361 claims
PfizerEliquis$33$67,49861 claims
AbbVieLinzess$37$45,30037 claims
BayerKerendia$20$23,82121 claims
MerckJanuvia$26$12,43715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 833 physician assistant providers in West Virginia.

Other physician assistant in Gilbert

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →